Exhibit 2
Joint Filing Statement
Pursuant to Rule 13d-1(k)(1)
The undersigned hereby consent and agree to the joint filing of Schedule 13D under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Landos Biopharma, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13D, thereby incorporating the same into such Schedule13D.
This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.
Dated: February 16, 2021
RTW INVESTMENTS, LP | ||
By: | /s/ Roderick Wong | |
Roderick Wong, M.D., Managing Partner | ||
RTW MASTER FUND, LTD. | ||
By: | /s/ Roderick Wong | |
Roderick Wong, M.D., Director | ||
RODERICK WONG | ||
By: | /s/ Roderick Wong | |
Roderick Wong, M.D., Individually |